NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 10907.35 2.15 0.02%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Molmed (BIT: MLM)

 

MLM Share Price

Open 0.44 Change Price %
High 0.44 1 Day 0.00 0.00
Low 0.43 1 Week 0.00 0.00
Close 0.44 1 Month 0.02 4.76
Volume 2515060 1 Year 0.09 25.71
52 Week High 0.54
52 Week Low 0.31
 
MLM Technical Analysis
3
As on 1st Nov 2017 MLM Share Price closed @ 0.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.43 & Buy for SHORT-TERM with Stoploss of 0.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 
BIT Italy Most Active Stocks
RN 0.04 0.00%
PMI 0.36 0.00%
TIT 0.75 1.35%
ISP 2.89 0.00%
F 6.94 -2.12%
TIS 0.04 0.00%
SPM 3.80 5.26%
ENEL 5.39 1.32%
TITR 0.62 1.64%
CRG 0.21 0.00%
 
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
AE 0.50 8.70%
AE 0.50 8.70%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
 
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
FTL 3.65 -7.36%
TBS 1.64 -6.82%
STEF 0.19 -5.00%
POPR 0.59 -4.84%
BIM 0.65 -4.41%
BIM 0.65 -4.41%
ZUCR 0.24 -4.00%
S24 1.70 -3.95%
 
 
MLM
Daily Charts
MLM
Intraday Charts
Whats New @
Bazaartrend
MLM
Free Analysis
 
MLM Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE0.45
RESISTANCE0.45
SUPPORT0.43
SUPPORT0.43
SUPPORT0.00
SUPPORT0.00
 
MLM Target for Month January
4th UP TARGET0.59
3rd UP TARGET0.54
2nd UP TARGET0.51
1st UP TARGET0.48
1st DOWN TARGET0.4
2nd DOWN TARGET0.37
3rd DOWN TARGET0.34
4th DOWN TARGET0.29
 
MLM Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
MLM Target for Year 2019
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
 
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
 
MLM Latest News
 
Your Comments and Response on Molmed
 
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.
 
© 2005-2018 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service